PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34127944-0 2021 Avasimibe Dampens Cholangiocarcinoma Progression by Inhibiting FoxM1-AKR1C1 Signaling. avasimibe 0-9 aldo-keto reductase family 1 member C1 Homo sapiens 69-75 34127944-2 2021 In the study, we proved that avasimibe retard cell proliferation and tumor growth of CCAs and identified FoxM1/AKR1C1 axis as the potential novel targets of avasimibe. avasimibe 157-166 aldo-keto reductase family 1 member C1 Homo sapiens 111-117 34127944-9 2021 Our study demonstrates a novel positive regulatory between FoxM1 and AKR1C1 contributing cell growth and tumor progression of CCA and avasimibe may be an alternative therapeutic option for CCA by targeting this FoxM1/AKR1C1 signaling pathway. avasimibe 134-143 aldo-keto reductase family 1 member C1 Homo sapiens 69-75 34127944-9 2021 Our study demonstrates a novel positive regulatory between FoxM1 and AKR1C1 contributing cell growth and tumor progression of CCA and avasimibe may be an alternative therapeutic option for CCA by targeting this FoxM1/AKR1C1 signaling pathway. avasimibe 134-143 aldo-keto reductase family 1 member C1 Homo sapiens 217-223 30774369-0 2019 Avasimibe inhibits tumor growth by targeting FoxM1-AKR1C1 in osteosarcoma. avasimibe 0-9 aldo-keto reductase family 1 member C1 Homo sapiens 51-57 30774369-6 2019 Avasimibe was found to inhibit cell proliferation and tumor growth by reducing the expression of AKR1C1 and FoxM1 in vivo and in vitro. avasimibe 0-9 aldo-keto reductase family 1 member C1 Homo sapiens 97-103